FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:539-540 February 14, 2002 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Bayer's voluntary withdrawal of cerivastatin from the U.S. market led to questions regarding the safety of all hydroxymethylglutaryl–coenzyme A reductase inhibitors, or statins. Myopathy and the rarer severe rhabdomyolysis are considered adverse events of therapy with this class of drugs.¹ Concomitant use of drugs that can increase blood levels of statins can increase the risk of myopathy, as can concomitant use of gemfibrozil.² We summarize the U.S. reports of fatal rhabdomyolysis associated with all six drugs in this class: lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin, and cerivastatin.

We reviewed reports in the Adverse Event Reporting System of the . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Barter, P. J., Rye, K.-A. (2008). Is There a Role for Fibrates in the Management of Dyslipidemia in the Metabolic Syndrome?. Arterioscler. Thromb. Vasc. Bio. 28: 39-46 [Abstract] [Full Text]  
• Alsheikh-Ali, A. A., Maddukuri, P. V., Han, H., Karas, R. H. (2007). Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer: Insights From Large Randomized Statin Trials. J Am Coll Cardiol 50: 409-418 [Abstract] [Full Text]  
• Marcoff, L., Thompson, P. D. (2007). The Role of Coenzyme Q10 in Statin-Associated Myopathy: A Systematic Review. J Am Coll Cardiol 49: 2231-2237 [Abstract] [Full Text]  
• Jose, J., Saravu, K., Shastry, B. A. (2007). Atorvastatin-induced early-onset rhabdomyolysis in a patient with nephrotic syndrome. Am J Health Syst Pharm 64: 726-729 [Abstract] [Full Text]  
• Ogasawara, A., Kume, T., Kazama, E. (2007). Effect of Oral Ketoconazole on Intestinal First-Pass Effect of Midazolam and Fexofenadine in Cynomolgus Monkeys. Drug Metab. Dispos. 35: 410-418 [Abstract] [Full Text]  
• Belay, B., Belamarich, P. F., Tom-Revzon, C. (2007). The Use of Statins in Pediatrics: Knowledge Base, Limitations, and Future Directions. Pediatrics 119: 370-380 [Abstract] [Full Text]  
• Kashani, A., Phillips, C. O., Foody, J. M., Wang, Y., Mangalmurti, S., Ko, D. T., Krumholz, H. M. (2006). Risks Associated With Statin Therapy: A Systematic Overview of Randomized Clinical Trials. Circulation 114: 2788-2797 [Abstract] [Full Text]  
• Waring, W S, Wrate, J, Bateman, D N (2006). Olanzapine overdose is associated with acute muscle toxicity. Hum Exp Toxicol 25: 735-740 [Abstract]  
• Strayer, S. M., Slawson, D. C., Shaughnessy, A. F. (2006). Disseminating Drug Prescribing Information: The Cox-2 Inhibitors Withdrawals. J. Am. Med. Inform. Assoc. 13: 396-398 [Abstract] [Full Text]  
• Arora, R., Liebo, M., Maldonado, F. (2006). Statin-Induced Myopathy: The Two Faces of Janus. J CARDIOVASC PHARMACOL THER 11: 105-112 [Abstract]  
• Briel, M., Schwartz, G. G., Thompson, P. L., de Lemos, J. A., Blazing, M. A., van Es, G.-A., Kayikcioglu, M., Arntz, H.-R., den Hartog, F. R., Veeger, N. J. G. M., Colivicchi, F., Dupuis, J., Okazaki, S., Wright, R. S., Bucher, H. C., Nordmann, A. J. (2006). Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials.. JAMA 295: 2046-2056 [Abstract] [Full Text]  
• Mastaglia, F L (2006). Drug induced myopathies. PN 6: 4-13 [Full Text]  
• Seachrist, J. L., Loi, C.-M., Evans, M. G., Criswell, K. A., Rothwell, C. E. (2005). Roles of Exercise and Pharmacokinetics in Cerivastatin-Induced Skeletal Muscle Toxicity. Toxicol Sci 88: 551-561 [Abstract] [Full Text]  
• Han, S. H., Quon, M. J., Koh, K. K. (2005). Beneficial Vascular and Metabolic Effects of Peroxisome Proliferator-Activated Receptor-{alpha} Activators. Hypertension 46: 1086-1092 [Abstract] [Full Text]  
• Wiviott, S. D., Cannon, C. P., Morrow, D. A., Ray, K. K., Pfeffer, M. A., Braunwald, E., for the PROVE IT-TIMI 22 Investigators, (2005). Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin Therapy: A PROVE IT-TIMI 22 Substudy. J Am Coll Cardiol 46: 1411-1416 [Abstract] [Full Text]  
• Chan, J., Hui, R. L, Levin, E. (2005). Differential Association Between Statin Exposure and Elevated Levels of Creatine Kinase. The Annals of Pharmacotherapy 39: 1611-1615 [Abstract] [Full Text]  
• Wysowski, D. K., Swartz, L. (2005). Adverse Drug Event Surveillance and Drug Withdrawals in the United States, 1969-2002: The Importance of Reporting Suspected Reactions. Arch Intern Med 165: 1363-1369 [Abstract] [Full Text]  
• McKenney, J. M. (2005). Efficacy and safety of rosuvastatin in treatment of dyslipidemia. Am J Health Syst Pharm 62: 1033-1047 [Abstract] [Full Text]  
• Stalenhoef, A. F.H. (2005). Management of mixed hyperlipidaemia. Eur Heart J 26: 856-857 [Full Text]  
• Horiguchi, A., Sumitomo, M., Asakuma, J., Asano, T., Asano, T., Hayakawa, M. (2004). 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitor, Fluvastatin, as a Novel Agent for Prophylaxis of Renal Cancer Metastasis. Clin. Cancer Res. 10: 8648-8655 [Abstract] [Full Text]  
• Beishuizen, E. D., van de Ree, M. A., Jukema, J. W., Tamsma, J. T., van der Vijver, J. C. M., Meinders, A. E., Putter, H., Huisman, M. V. (2004). Two-Year Statin Therapy Does Not Alter the Progression of Intima-Media Thickness in Patients With Type 2 Diabetes Without Manifest Cardiovascular Disease. Diabetes Care 27: 2887-2892 [Abstract] [Full Text]  
• Graham, D. J., Staffa, J. A., Shatin, D., Andrade, S. E., Schech, S. D., La Grenade, L., Gurwitz, J. H., Chan, K. A., Goodman, M. J., Platt, R. (2004). Incidence of Hospitalized Rhabdomyolysis in Patients Treated With Lipid-Lowering Drugs. JAMA 292: 2585-2590 [Abstract] [Full Text]  
• Psaty, B. M., Furberg, C. D., Ray, W. A., Weiss, N. S. (2004). Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis. JAMA 292: 2622-2631 [Abstract] [Full Text]  
• Strom, B. L. (2004). Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: A Counterpoint. JAMA 292: 2643-2646 [Full Text]  
• Psaty, B. M., Furberg, C. D., Ray, W. A., Weiss, N. S. (2004). Authors' Reply to Bayer's Response to "Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis". JAMA 292: 2658-2659 [Full Text]  
• Shitara, Y., Hirano, M., Sato, H., Sugiyama, Y. (2004). Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:SLC21A6)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction between Cerivastatin and Gemfibrozil. J. Pharmacol. Exp. Ther. 311: 228-236 [Abstract] [Full Text]  
• Nissen, S. E. (2004). High-Dose Statins in Acute Coronary Syndromes: Not Just Lipid Levels. JAMA 292: 1365-1367 [Full Text]  
• Bergman, A. J., Murphy, G., Burke, J., Zhao, J. J., Valesky, R., Liu, L., Lasseter, K. C., He, W., Prueksaritanont, T., Qiu, Y., Hartford, A., Vega, J. M., Paolini, J. F. (2004). Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in Humans. J Clin Pharmacol 44: 1054-1062 [Abstract] [Full Text]  
• Lazar, H. L. (2004). Role of statin therapy in the coronary bypass patient. Ann. Thorac. Surg. 78: 730-740 [Abstract] [Full Text]  
• Solomon, D. H., Schneeweiss, S., Levin, R., Avorn, J. (2004). Relationship Between COX-2 Specific Inhibitors and Hypertension. Hypertension 44: 140-145 [Abstract] [Full Text]  
• Wooltorton, E. (2004). Rosuvastatin (Crestor) and rhabdomyolysis. CMAJ 171: 129-129 [Full Text]  
• Stricker, B. H., Psaty, B. M (2004). Detection, verification, and quantification of adverse drug reactions. BMJ 329: 44-47 [Full Text]  
• Bellosta, S., Paoletti, R., Corsini, A. (2004). Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions. Circulation 109: III-50-III-57 [Abstract] [Full Text]  
• Roten, L., Schoenenberger, R. A, Krahenbuhl, S., Schlienger, R. G (2004). Rhabdomyolysis in Association with Simvastatin and Amiodarone. The Annals of Pharmacotherapy 38: 978-981 [Abstract] [Full Text]  
• Ko, D. T., Mamdani, M., Alter, D. A. (2004). Lipid-Lowering Therapy With Statins in High-Risk Elderly Patients: The Treatment-Risk Paradox. JAMA 291: 1864-1870 [Abstract] [Full Text]  
• Gladding, P., Pilmore, H., Edwards, C. (2004). Potentially Fatal Interaction between Diltiazem and Statins. ANN INTERN MED 140: W-31-W-31 [Full Text]  
• Edison, R. J., Muenke, M. (2004). Central Nervous System and Limb Anomalies in Case Reports of First-Trimester Statin Exposure. NEJM 350: 1579-1582 [Full Text]  
• Dreier, J. P., Endres, M. (2004). Statin-associated rhabdomyolysis triggered by grapefruit consumption. Neurology 62: 670-670 [Full Text]  
• Law, M R, Wald, N J, Rudnicka, A R (2003). Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326: 1423- [Abstract] [Full Text]  
• Thompson, P. D., Clarkson, P., Karas, R. H. (2003). Statin-Associated Myopathy. JAMA 289: 1681-1690 [Abstract] [Full Text]  
• Gotto, A. M. Jr (2003). Safety and Statin Therapy: Reconsidering the Risks and Benefits. Arch Intern Med 163: 657-659 [Full Text]  
• Ballantyne, C. M., Corsini, A., Davidson, M. H., Holdaas, H., Jacobson, T. A., Leitersdorf, E., Marz, W., Reckless, J. P. D., Stein, E. A. (2003). Risk for Myopathy With Statin Therapy in High-Risk Patients. Arch Intern Med 163: 553-564 [Abstract] [Full Text]  
• Barandier, C., Ming, X.-F., Yang, Z. (2003). Small G Proteins as Novel Therapeutic Targets in Cardiovascular Medicine. Physiology 18: 18-22 [Abstract] [Full Text]  
• Grundy, S. M. (2002). Can Statins Cause Chronic Low-Grade Myopathy?. ANN INTERN MED 137: 617-618 [Full Text]  
• Pasternak, R. C., Smith, S. C. Jr, Bairey-Merz, C. N., Grundy, S. M., Cleeman, J. I., Lenfant, C. (2002). ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 40: 567-572 [Full Text]  
• Kennedy, H. L., Rosenson, R. S. (2002). Physicians' interpretation of "class effects": A need for thoughtful re-evaluation. J Am Coll Cardiol 40: 19-26 [Abstract] [Full Text]